Trial · NCT07535034
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
NCT07535034, Phase 2, Recruiting, Crystalys Therapeutics
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants. Trials, record NCT07535034. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07535034
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
- NCT number
- NCT07535034
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 90 participants, estimated
- Lead sponsor
- Crystalys Therapeutics
- Conditions
- Gout
- Interventions
- Dotinurad, Placebo
- First posted
- 2026-04-16
- Last updated
- 2026-09-28
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With an sUA Level <6.0 mg/dL at Week 24 | Week 24 | |
| Secondary | Percentage of Participants With an sUA Level <6.0 mg/dL at Weeks 16, 20 and 24 | Weeks 16, 20 and 24 | |
| Secondary | Percentage of Participants With an sUA Level <6.0 <5.0, <4.0, and <3.0 mg/dL at Each Visit | Up to Week 40 | |
| Secondary | Mean Change From Baseline in sUA at Week 24 | Baseline and Week 24 | |
| Secondary | Absolute Change from Baseline in sUA Levels at Each Visit | Baseline to Week 40 | |
| Secondary | Percent Change from Baseline in sUA Levels at Each Visit | Baseline to Week 40 | |
| Secondary | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Treatment Periods 1 and 2 | Screening to Week 36 | Any clinically significant changes from baseline in safety laboratory values and vital signs will be reported as AEs per investigators discretion. |
| Secondary | Number of Participants With TEAEs and SAEs Throughout the Study | Screening to Week 40 | Any clinically significant changes from baseline in safety laboratory values and vital signs will be reported as AEs per investigators discretion. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07535034
GET https://conductscience.org/api/trials/v1/NCT07535034/registered